ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Oncoclinicas do Brasil (ONCO3.SA)
Oncoclinicas do Brasil stock price today, ATLAS forecast and fair value
Healthcare · Medical Care Facilities · B3 (Brasil Bolsa Balcão) · Brazil
R$0.840▼ -20.75%
Prices as of Oct 26, 2026 · BRL
Chance of rising in 1 month
40%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Oncoclinicas do Brasil in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Oncoclinicas do Brasil
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Oncoclinicas do Brasil a 40% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between R$0.585 and R$0.998; in 9 out of 10, between R$0.365 and R$1.60. Estimated annual volatility is 167%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- R$1.2B
- Market cap (USD)
- $229M
- 52-week high
- R$3.07
- 52-week low
- R$0.530
- Revenue (12 months)
- R$5.0B
- Gross margin
- 27.3%
- Operating margin
- -27.7%
- Net margin
- -84.8%
- Beta
- 1.18
What this means
ATLAS does not publish a fair value for ONCO3.SA right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks ONCO3.SA has traded between R$0.530 and R$3.07. Today it is 72.6% below that high and 58% above its low.
Its beta is 1.18: it tends to move more than the market, both up and down.
About the company
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America.
Want to see everything about Oncoclinicas do Brasil?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Oncoclinicas do Brasil do?
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America.
What is the chance ONCO3.SA goes up next month?
40%: somewhat worse than a coin flip. In half of the simulated outcomes, ONCO3.SA ends the month between R$0.585 and R$0.998.
How big is Oncoclinicas do Brasil and what is its P/E ratio?
Oncoclinicas do Brasil's market capitalization is R$1.2B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is ONCO3.SA?
ATLAS estimates annual volatility at 167%. In a typical month, half of the outcomes end between R$0.585 and R$0.998.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer